The plasma fractionation market is projected to reach USD 34.9 billion by 2024 from USD 25.4 billion in 2019, at a CAGR of 6.6% during the forecast period. Market growth can be attributed to factors such as growing use of immunoglobulins in various therapeutic areas, rising geriatric population across the globe, the growing prevalence of respiratory diseases and AATD driving the uptake of alpha-1-antitrypsin, and increase in plasma collection. The indications for plasma products are also being expanded, which is expected to support market growth in the coming years. Another key trend in this market is the rising installation of fractionators in plasma collection centers.

“Global overactive bladder treatment market is projected to grow at a CAGR of 2.9%.”

1 Increasing Adoption of Targeted Therapy Over Traditional Therapy 2 Emergence of Biosimilars 3 Increasing Demand for Mabs 4 High Prevalence Rate of Lifestyle Diseases 5 Fast Track and Orphan Drug Designations

Viral vectors are modified viruses developed using sophisticated DNA recombination techniques. This alteration makes the viruses safe for the transfer of genes of interest to target cells or tissues for therapeutic purposes. Various types of viruses (e.g., adenoviruses, retroviruses, poxviruses, adeno-associated viruses and herpes simplex viruses) are currently being investigated for their potential in gene therapy.